Solid Tumors

Phase 1 Study of Single-Agent ONX 0912
Currently enrolling
Study Design: Non-randomized, open-label, dose escalation study
Patients: Patients with advanced refractory or recurrent solid tumors
Purpose: To evaluate safety and tolerability including dose limiting and maximum tolerated dose, to determine the pharmacokinetics  and pharmacodynamics of ONX 0912
Locations: Multiple centers throughout the U.S.

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204